Tiziana Life Sciences (TLSA) said Thursday that preclinical studies of foralumab, a nasal anti-CD3 monoclonal antibody, in traumatic spinal cord injury showed notable improvements in motor functions.
The company said it is also evaluating the drug candidate in a phase 2a study for patients with non-active secondary progressive multiple sclerosis.
Shares of Tiziana Life Sciences were up 3.2% in recent trading.
Price: 0.82, Change: +0.03, Percent Change: +3.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.